30 Richmond Road, Homebush West, NSW 2140
Contact Us

(02) 8415 7300

Contact details

Memphasys Ltd
(ASX: MEM)

30 Richmond Road,

Homebush West, NSW 2140

France


Phone: (02) 8415 7300

Email: info@memphasys.com

Stay in touch:

Board of Directors

Robert Cooke - Non-Executive Chairman

Robert Cooke

Non-Executive Chairman

More than 40 years in healthcare, spanning executive leadership of publicly listed and privately owned healthcare companies, overseeing numerous M&A transactions, and management of private and public hospitals in Australia, Asia and the UK.

MD & CEO of Healthscope (2010-2017), a leading private hospital, medical centre and pathology company. Currently Non-Executive Chair of OptiScan Imaging (ASX: OIL), a global leader in the development of microscopic imaging.
 

Alison Coutts - Managing Director and CEO

Alison Coutts 

Managing Director and CEO 

Ms Alison Coutts is currently the Managing Director and CEO of Memphasys Ltd. She has a Chemical Engineering degree and a Graduate Diploma in Biotechnology from the University of Melbourne and an MBA with distinction from Melbourne Business School.

Ms Coutts has extensive experience across a number of industry sectors and disciplines. This includes international engineering project management with Bechtel Corporation in the UK, USA and New Zealand, strategy consulting with Boston Consulting group, executive search with Egon Zehnder International, investment banking at eG Capital, which she co-founded, technology commercialisation over the past 15 years and executive management, currently with Memphasys Ltd.

She is formerly Chair of CSIRO’s Health Sector Advisory Council and was a co-founder and director of eG Capital, which was a preeminent financial advisory firm in the Australian Life Sciences sector.

She was also the former Chairman of Biolink Associates. Until March 2016 Ms Coutts was a Non-Executive Director of DataDot Ltd .

Whilst at eG Capital (2001-2008) Ms Coutts was responsible for analysing the biotech sector and determining which companies eG Capital would support. She was responsible for a number of IPOs and secondary raisings of client companies, and was the key person promoting eG Capital and its clients to the financial community and to the media.

In 2009, Ms Coutts co-founded Mariposa Healthcare Pty Ltd, a drug development company focussed on COPD with two drugs in phase II development.

In 2010, she co-founded Micro-X Ltd, a company which listed on the ASX in December 2015 for $40 million. Micro-X is producing a novel ultra -small and light X-ray machine using carbon nano tubes.

Andrew Goodall - Non-Executive Director 

Andrew Goodall 

Non-Executive Director 

Mr Goodall is a Non-Executive Director of Memphasys Limited and has served as a Director on the Board since March 2012.  

He is also a member of the Company's Audit and Risk and Nomination and Remuneration Committees and has been a respected member of Memphasys' committees since joining the board.

Mr Goodall is the Company's largest shareholder and has been a significant shareholder in Memphasys for many years.  

Mr Goodall brings a wealth of business, and commercial experience as well as considered judgement to his role as a Memphasys' Director. 

He is an entrepreneur who has successfully established a number of businesses throughout his career in Australia and New Zealand.

Having had extensive experience in Commercial Property Investment, Mr Goodall is currently involved in the management of his substantial commercial property interests in New Zealand. 

Mr Goodall also has a rural property in northern NSW.

Paul Wright - Non-Executive Director 

Paul Wright

Non-Executive Director 

Mr Wright is a Non-Executive Director of Memphasys Limited and was appointed to the Board in March 2020.  He holds a Master’s degree in Engineering from Cambridge University, UK and is a Fellow of the Australian Institute of Company Directors. 

With more than 30 years’ experience as a highly skilled executive in strategic consulting and the development and sales of innovative medical devices and diagnostic tools, Mr Wright is well positioned to assist Memphasys in the commercialisation of its Felix device. 

Mr Wright’s background includes developing and implementing commercialisation strategies from early research and development through to developing global product sales channels.

Mr Wright has experience in building distribution partnerships and the direct selling and marketing of highly innovative products internationally. 

For the past two decades, he has worked as CEO for three leading international Australian technology companies focussed on developing, manufacturing and marketing of medical devices and diagnostic instruments. 

Mr Wright is currently a non-executive director of design, engineering and technology commercialisation company Hydrix Ltd and an advisory board member for unlisted digital wastewater services company, Waterwerx Pty Ltd.